Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02959827 · ClinicalTrials.gov registry record
Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 2,320
- Enrollment target
NCT02959827: Completed study, sponsored by Bayer.
NCT02959827 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 2,320 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02959827 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 2,320 participants
- Enrollment target
Study Summary
This study will estimate the incidence of hypothyroidism in a pediatric population of children under age 4, based on data from the US-based Kaiser Permanente Northern California database, which were exposed to iodinated contrast agent through having a diagnostic procedure.
Primary Outcome
Incidence density rates (IDR) were calculated as the number of cases over the person time at risk where the numerator was the number of cases and the denominator was the person years at risk.
Interventions
- DRUG Iodinated contrast agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,320 participants |
| Start Date | 2016-10-15 |
| Est. Completion | 2017-06-15 |
What the finished NCT02959827 record still lists
NCT02959827 is an observational study that tracks outcomes without assigning an intervention. Its 2,320 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Iodinated contrast agents is the first listed.
NCT02959827 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02959827 about?
NCT02959827 is a clinical study titled "Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States". This study will estimate the incidence of hypothyroidism in a pediatric population of children under age 4, based on data from the US-based Kaiser Permanente Northern California database, which were exposed to iodinated contrast agent through having a diagnostic procedure.
What is the current status of trial NCT02959827?
This trial is currently completed. The enrollment target is 2,320 participants. The study started on 2016-10-15. Estimated completion is 2017-06-15.
What interventions are being tested in trial NCT02959827?
The interventions under investigation include: Iodinated contrast agents (DRUG).
Who is sponsoring clinical trial NCT02959827?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05700760 · 2,320 participants · NA
The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
- NCT06824194 · 2,320 participants · Phase 3
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- NCT06679140 · 2,330 participants · Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- NCT05485961 · 2,310 participants · Phase 2
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI